Three short videos that detail new treatments and advances made against Myeloma.

Of interest in high-risk refractory/relapsed cases is the effectiveness of Chimeric Antigen Receptor T-Cells (CAR-T). The problem seems to be one of dosage or possibly the via of administration, as the CAR-T Cells do provoke a rather serious immune response in the patient. They are also moving toward transplanting early on, which is another consideration.